
Al Sandrock
Biogen's Al Sandrock says the FDA needs to approve their controversial Alzheimer's drug — now
Al Sandrock is an outspoken champion for aducanumab. And he clearly believes that the FDA needs to approve it now — overriding the controversy it’s sparked — or face criticism from patients clamoring for some kind of medication to slow the disease.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters